Giovanni Frisoni

Giovanni Frisoni is a Full Professor of Neuroscience at the University of Geneva's Faculty of Medicine, specializing in Alzheimer's disease research and diagnostics. He leads multiple European consortia including the AMYPAD project and contributes to European task forces for brain health services. His work bridges clinical neurology, neuroimaging, and biomarker development.

Frisoni's research focuses on the intersection of neuroimaging biomarkers, cognitive decline, and Alzheimer's disease pathology. His team investigates amyloid and tau dynamics using PET imaging, develops blood-based diagnostic workflows, and explores novel therapeutic avenues including gut-brain axis interventions. Recent work demonstrates leadership in translating biomarker research into clinical practice through European intersocietal recommendations.

His publication record shows a clear evolution from foundational neuroimaging studies (2020-2022) toward clinical implementation frameworks (2023-2025). Current work emphasizes blood biomarkers for tau-PET referral optimization, fecal microbiota transplantation effects, and anti-amyloid therapy guidelines. The research spans basic science (mouse models), translational studies (imaging-biomarker correlations), and health services research (diagnostic pathways).

Key Scientific Contributions:

• Developed clinical implementation frameworks for amyloid and tau PET
• Pioneered blood biomarker workflows for memory clinic diagnostics
• Advanced understanding of gut-brain axis in Alzheimer's pathology
• Shaped European diagnostic guidelines through multisociety consensus

Frisoni actively mentors junior researchers including Ribaldi, Altomare, and Ceyzeriat, who frequently co-lead projects. His work receives substantial European funding through consortia like AMYPAD and Euro-PAD. Current projects include the PreTAD dementia risk estimation initiative and RADAR-AD remote monitoring technologies. He maintains strong collaborations across European memory clinics and imaging centers.

His laboratory focuses on multimodal biomarker integration, particularly combining PET imaging with fluid biomarkers and EEG. Recent technical advances include AI applications for generating FDG-PET images from amyloid scans and connectome identifiability metrics for Alzheimer's disease.